Table 1.

Laboratory and demographic data of the studied groups.

	G1	G2	G3	G4	P1	P2	P3	P4	P5	P6
FEV1% predicted	66.3± 1.3	68.8± 1.2	67.2 ± 0.9	91.8± 1.1	<0.001*	0.8	<0.001*	<0.001*	<0.001*	<0.001*
Total sIgE (IU/mL)	219.1± 14.9	132.8± 30.3	183.8± 17.6	52.0± 12.59	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
Peripheral eosinophilic%	5.2± 0.69	8.13± 0.83	7.66± 1.08	1.7± 0.71	<0.001*	0.1	<0.001*	<0.001*	<0.001*	0.03
sECP (µg/L)	36.21± 7.05	74.33± 12.38	49.7± 8.25	18.32± 5.19	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
sICAM-1 (ng/mL)	716± 56.4	711.5± 70.9	704± 62.2	402 ± 0.7	<0.001*	0.9	0.3	<0.001*	0.2	<0.001*
sVCAM-1 (ng/mL)	879.9± 269.1	847.2± 230.2	864± 239.2	550 ± 0.3	<0.001*	0.7	0.8	<0.001*	0.3	<0.001*
sIL-2R (pg/mL)	3922± 379.1	3453.8± 544.05	3433.7± 349.2	1980 ± 0.5	<0.001*	0.3	<0.001*	<0.001*	<0.001*	<0.001*
Age (y)	9.7± 2.3	9.8± 2.3	9.3± 1.2	10.2± 0.22	0.66	0.66	0.66	0.66	0.66	0.66
Male	25 (52.08%)	23 (53.4%)	27 (51.92%)	21 (47.72%)	0.6	0.6	0.6	0.6	0.6	0.6
Female	23 (47.9%)	20 (46.51%)	25 (48.07%)	23 (52.27%)	0.62	0.62	0.62	0.62	0.62	0.62
Duration of asthma (y)	5.4 ± 2.4	5.5 ± 3.4	5.3 ± 2.4			0.71	0.71		0.71
FH: positive	28 (58.3%)	24 (55.81%)	29 (55.76%)	Negative
FH: negative	20 (41.6%)	19 (44.18%)	23 (44.23%)	Negative

Data are expressed as mean (SD); *P < 0.05 is considered significant.

IgE: immunoglobulin E, sECP: serum eosinophilic cationic protein, and FH: family history of asthma.

G1: shortness of breath group (SOB) group, G2: cough group, G3: Wheezy group, and G4: controls.

P1 : G2 versus G4, P2 : G2 versus G3, P3 : G2 versus G1, P4 : G3 versus G4 , P5: G3 versus G1, and P6 : G1 versus G4.